High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease
Status:
Not yet recruiting
Trial end date:
2026-02-20
Target enrollment:
Participant gender:
Summary
Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder with high prevalence in
patients suffering from chronic liver diseases [1]. NAFLD is characterized by the
accumulation of > 5% of fat deposits in hepatocytes (hepatic steatosis) with no known other
reasons for steatosis as excessive alcohol intake.The global prevalence of NAFLD differs
depending on the population reaching 13% in Africa, 32% in the Middle East, and 30 % in the
United States